BioMarin Pharmaceutical Inc. vs Galapagos NV: Annual Revenue Growth Compared

BioMarin vs. Galapagos: A Decade of Divergent Growth

__timestamp	BioMarin Pharmaceutical Inc.	Galapagos NV
Wednesday, January 1, 2014	751040000	69368000
Thursday, January 1, 2015	889895000	39563000
Friday, January 1, 2016	1116854000	129517000
Sunday, January 1, 2017	1313646000	127087000
Monday, January 1, 2018	1491212000	288836000
Tuesday, January 1, 2019	1704048000	844986000
Wednesday, January 1, 2020	1860455000	478053000
Friday, January 1, 2021	1846275000	484846000
Saturday, January 1, 2022	2096039000	505280000
Sunday, January 1, 2023	2419226000	239724000

Unleashing the power of data

BioMarin vs. Galapagos: A Decade of Revenue Growth

In the competitive landscape of biotechnology, BioMarin Pharmaceutical Inc. and Galapagos NV have charted distinct paths over the past decade. From 2014 to 2023, BioMarin's revenue surged by over 220%, reflecting its robust pipeline and strategic market positioning. In contrast, Galapagos NV experienced a more volatile trajectory, with revenue peaking in 2019 before declining by 72% by 2023. This divergence highlights the contrasting strategies and market responses of these two biotech giants. BioMarin's consistent growth underscores its focus on niche markets and innovative therapies, while Galapagos's fluctuations suggest challenges in sustaining its initial momentum. As the biotech sector continues to evolve, these companies' financial narratives offer valuable insights into the dynamics of innovation, market adaptation, and strategic foresight.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025